IMMNOV Stock Overview
Immunovia AB (publ), a diagnostic company, develops and commercializes blood-based diagnostics for cancer in Sweden and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Immunovia AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr2.07 |
| 52 Week High | kr4.95 |
| 52 Week Low | kr0.51 |
| Beta | 2.73 |
| 1 Month Change | 55.26% |
| 3 Month Change | 15.23% |
| 1 Year Change | -56.02% |
| 3 Year Change | -98.28% |
| 5 Year Change | -98.81% |
| Change since IPO | -93.05% |
Recent News & Updates
Recent updates
Here's Why We're Watching Immunovia's (STO:IMMNOV) Cash Burn Situation
Apr 20
We're Keeping An Eye On Immunovia's (STO:IMMNOV) Cash Burn Rate
Dec 09Is Immunovia (STO:IMMNOV) In A Good Position To Invest In Growth?
May 13Here's Why We're Not Too Worried About Immunovia's (STO:IMMNOV) Cash Burn Situation
Jan 18We Think Immunovia (STO:IMMNOV) Can Afford To Drive Business Growth
Aug 28What Kind Of Investors Own Most Of Immunovia AB (publ) (STO:IMMNOV)?
Mar 09Here's Why We're Not Too Worried About Immunovia's (STO:IMMNOV) Cash Burn Situation
Feb 03
Immunovia AB (publ)'s (STO:IMMNOV) Intrinsic Value Is Potentially 72% Above Its Share Price
Dec 30Insider Buying: The Immunovia AB (publ) (STO:IMMNOV) Director Just Bought kr293k Worth Of Shares
Dec 03Shareholder Returns
| IMMNOV | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | 14.1% | -3.4% | -1.6% |
| 1Y | -56.0% | -13.6% | 7.8% |
Return vs Industry: IMMNOV underperformed the Swedish Medical Equipment industry which returned -13.6% over the past year.
Return vs Market: IMMNOV underperformed the Swedish Market which returned 7.8% over the past year.
Price Volatility
| IMMNOV volatility | |
|---|---|
| IMMNOV Average Weekly Movement | 26.1% |
| Medical Equipment Industry Average Movement | 7.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 12.8% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: IMMNOV's share price has been volatile over the past 3 months.
Volatility Over Time: IMMNOV's weekly volatility has decreased from 38% to 26% over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 11 | Jeff Borcherding | www.immunovia.com |
Immunovia AB (publ), a diagnostic company, develops and commercializes blood-based diagnostics for cancer in Sweden and internationally. It offers IMMray PanCan-d, a blood-based test for the early detection of pancreatic cancer. The company was incorporated in 2007 and is headquartered in Lund, Sweden.
Immunovia AB (publ) Fundamentals Summary
| IMMNOV fundamental statistics | |
|---|---|
| Market cap | kr93.52m |
| Earnings (TTM) | -kr309.44m |
| Revenue (TTM) | kr1.58m |
59.4x
P/S Ratio-0.3x
P/E RatioIs IMMNOV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMMNOV income statement (TTM) | |
|---|---|
| Revenue | kr1.58m |
| Cost of Revenue | kr6.68m |
| Gross Profit | -kr5.11m |
| Other Expenses | kr304.33m |
| Earnings | -kr309.44m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 25, 2024
| Earnings per share (EPS) | -6.83 |
| Gross Margin | -324.25% |
| Net Profit Margin | -19,646.86% |
| Debt/Equity Ratio | 0% |
How did IMMNOV perform over the long term?
See historical performance and comparison